Barclays PLC Increases Stake in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Barclays PLC grew its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 146.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 78,021 shares of the biopharmaceutical company’s stock after acquiring an additional 46,370 shares during the quarter. Barclays PLC owned about 0.16% of Puma Biotechnology worth $199,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Frazier Life Sciences Management L.P. boosted its position in shares of Puma Biotechnology by 8.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after acquiring an additional 246,264 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Puma Biotechnology by 1.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock valued at $5,715,000 after acquiring an additional 23,600 shares during the last quarter. Great Point Partners LLC boosted its position in shares of Puma Biotechnology by 10.6% during the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock valued at $4,846,000 after acquiring an additional 142,916 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Puma Biotechnology by 98.5% during the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after acquiring an additional 366,653 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Puma Biotechnology by 6.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock valued at $1,975,000 after acquiring an additional 37,684 shares during the last quarter. 61.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on PBYI shares. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Monday, December 23rd. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Puma Biotechnology Stock Up 0.3 %

Shares of PBYI opened at $2.98 on Wednesday. The company has a market cap of $146.29 million, a PE ratio of 6.21 and a beta of 1.10. The business has a fifty day moving average of $3.05 and a 200 day moving average of $2.99. Puma Biotechnology, Inc. has a 52-week low of $2.22 and a 52-week high of $7.73. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same period last year, the company earned $0.12 earnings per share. On average, sell-side analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Insider Transactions at Puma Biotechnology

In other news, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This trade represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the sale, the insider now owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.